Form 4: Mineralys Therapeutics Director Alexander M. Gold Acquires Stock Options
SEC Form 4 Filing
Director Alexander M. Gold of Mineralys Therapeutics, Inc. reports acquisition of stock options.
Summary
- On February 13, 2025, Alexander M. Gold, a director of Mineralys Therapeutics, Inc., acquired 32,900 stock options.
- The stock options have an exercise price of $10.20.
- The options vest in 12 substantially equal monthly installments following the grant date and expire on February 13, 2035.
- Following the transaction, Mr. Gold directly owns 32,900 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be interpreted as a sign of confidence, but it doesn't inherently indicate overwhelmingly positive or negative sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of earliest transaction: acquisition of stock options. |
| 02/13/2035 | Expiration date of the stock options. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Mineralys Therapeutics, Director, Stock Options, Form 4, MLYS, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.